王科明7-23南京省肿瘤年会.pptVIP

乳 腺 癌 化 疗 研 究 精 选 ??2011ASCO 王 科 明 南 京 医 科 大 学 第 二 附 属 医 院 肿 瘤 科1 高剂量密度ETC方案及常规方案治疗高 危 乳 癌 的 8 年 随 访 结 果 Intense dose-dense idd sequential chemotherapy with epirubicin E, paclitaxel T, and cyclophosphamide C ETC compared with conventionally scheduled chemotherapy in high-risk breast cancer patients 3+LN: Eight-year follow-up analysisV. Moebus, C. Thomssen, H. Lueck, et al. ASCO Annual Meeting Abstract No: 1018Background德 国AGO 组 、 多 中 心 、III trial 98.12 ~03.4 65 , 3+LN 。 N1284化疗方案 试验组:E 150 mg/m2+P 225 mg/m2 + CTX 2500 mg/m2 , q2w ×3cycles , G-CSF 5?g/kg/SC day 3-10对照组:EC 90/600 mg/m2 ×4序贯T 175 mg/m2 ×4 ,q3wN1284 腋淋巴 结10个 42% 试验组N641 对 照组N611BackgroundMore than 97% of the women in the conventional arm received the full protocol dose per administered cycles? In the IDD-ETC arm,we observed virtually no dose reduction with epirubicin mean dose per cycle, 149 mg/m2 and with paclitaxel mean dose per cycle, 223mg/m2, and we observed only a minor dose reduction with cyclophosphamidemean dose per cycle, 2,444mg/m2 Overall,93%of all cycles administered in the IDD- ETC arm were applied at full dose.5 年 随 访 结 果 J CLin Oncol.2010 Jun 10;2817:2874-80 5 年 随 访 结 果 A 淋巴结4-9个 B 淋巴结10 5年EFS8年随访结果No severe late cardiotoxicity was reported. 8 pts in the idd ETC-Arm developed AML or MDS? At a median follow-up of 8 years 231 pts in the idd ETC arm vs. 285 pts in the standard arm had relapsed HR 0.71 95% CI: 0.59 - 0.84p0.0001 死亡:试验组Vs对照组:172 Vs 205 p0.0086; HR: 0.76 95% CI: 0.62-0.93? 8年 OS:试验组Vs对照组: 71% vs. 65% 本结果与激素受体、月经状况、淋巴结数 4- 9; 9 HER2无关. 2 贝伐单抗联合紫杉醇一线治疗HER2阴性 转 移 性 乳 癌 的 疗 效 及 安 全 性 First-line bevacizumab B pluspaclitaxel P in HER2- negative HER2-ve metastatic breast cancer mBC: Efficacy and safety in an Italian multicenter retrospective study. D. Andreis, G. Scandurra, D. Santini, et al. ASCO Annual Meeting Abstract No: e11502Background:The combination of B with P as first-line treatment for patients pts with HER2- mBC showed clinical benefits in ter